跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE

首页临床试验发起方与机构ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE

ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE

ACTIVE

1112 Montana Ave 916, 马萨诸塞州米德尔塞克斯县, Massachusetts, 美国www.ocata.comHolding37 名员工成立于: 1994-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

10

1 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

1994

概览

试验阶段分布

阶段

试验数

占比

1 期

6

60.0%

2 期

1

10.0%

试验状态分布

已完成

6

60.0%

Enrolling By Invitation

1

10.0%

招募中

2

20.0%

撤回

1

10.0%

相关临床试验

该机构主办的试验（10）

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

Aug 202630 名受试者

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Jul 201842 名受试者

A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy

Enrolling By Invitation

Jan 201836 名受试者

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

Feb 201311 名受试者

A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Jan 201312 名受试者

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Jul 201213 名受试者

Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Dec 201112 名受试者

第 1 页，共 2 页

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验10
药物批准
资讯

返回机构列表